Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations

LESSONS LEARNED. This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations provides long‐term control for the primary lung lesion, and 1‐year prog...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Zheng, LinPeng, Wang, Yanmei, Xu, Zihan, Yang, Qiao, Zhu, Guangkuo, Liao, Xing‐Yun, Chen, Xiewan, Zhu, Bo, Duan, Yuzhong, Sun, Jianguo
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693693/
https://ncbi.nlm.nih.gov/pubmed/31040256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0285
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares